Latest Eisai News & Updates

See the latest news and media coverage for Eisai. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Eisai

Human health care pharmaceutical company

eisai.com
Headquarters
Bunkyo-Ku, Japan
Company type
Public company
Number of employees
1,000–5,000
Industry
Pharmaceuticals

Last updated

Latest news about Eisai

In short: Eisai achieved global regulatory milestones for its Alzheimer’s drug Leqembi and reported 26% net income growth for its first quarter.

Company announcements

Eisai

Eisai opens new Global Capability Centre

The IT hub in Visakhapatnam, India, standardizes global IT operations and drives digital transformation. An opening ceremony celebrated its launch.

Eisai

Eisai ranks 36th in Global 100 sustainability list

It marks Eisai's tenth inclusion and highest rank among global pharmaceutical companies. Evaluation based on UN SDGs, sustainable revenue, and investment.

Unlock all announcements with a

Media coverage

Nikkei

Eisai and Biogen, subcutaneous formulation "Leqembi Subcutaneous Injection 250mg Pen ...

[Press Release] Announcement Date: September 16, 2026 The subcutaneous formulation "Leqembi(R) Subcutaneous Injection 250mg Pen" of the early Alzheimer's disease treatment agent "Leqembi(R)" has obtained approval in Japan. This is the first and only amyloid-targeting therapy available for home administration (*) for Alzheimer's disease, a progressive condition, in Japan. Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer CEO: Haruo Naito, hereinafter "Eisai") and Biogen Inc. (Nasdaq ...

Nikkei

Eisai's subcutaneous formulation of "lecanemab" approved in China, launch scheduled for fiscal 2026

On the 3rd, Eisai announced that it has received approval from the National Medical Products Administration (NMPA) of China for the subcutaneous formulation of the Alzheimer's disease treatment drug "lecanemab" as an initial therapy. The product is scheduled to be launched during fiscal 2026. This marks the second such subcutaneous formulation of lecanemab to be approved worldwide...

Nikkei

Eisai and Biogen, Health Canada's early-stage Alzheimer's ...

[Press Release] Date of Announcement: September 1, 2026 Health Canada has published its final recommendation supporting public reimbursement for the early Alzheimer's disease treatment "Leqembi(R)" (lecanemab), marking an important step forward in expanding access to Leqembi for eligible patients in Canada. Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer & CEO: Haruo Naito, hereinafter "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Massachusetts, U.S....

Unlock all articles with a

Never miss news about Eisai

Track Eisai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eisai competitors & trending companies

Browse news for competitors to Eisai and other trending companies.